Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR supplementation after acute proximal DVT to enhance thrombus resolution
NL-OMON52521Phase 3Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of hydroxyethylrutoside in deep vein thrombosis (DVT) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Residual venous obstruction in proximal venous segments. Started Dec 2020; status: active, not recruiting.
02
Drugs
hydroxyethylrutoside
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NL-OMON52521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52521.